Relationship between serum Hepatitis B virus (HBV) DNA levels and HBe Ag status in patientswith Hepatitis B virus infection
Veenu Gupta, Deepinder Kaur, Vandana Kaushal
Hepatitis B, HBV–DNA, HBe Ag, Real time-PCR
Citation Information :
Gupta V, Kaur D, Kaushal V. Relationship between serum Hepatitis B virus (HBV) DNA levels and HBe Ag status in patientswith Hepatitis B virus infection. J Gastrointest Infect 2012; 2 (1):43-45.
Background: Hepatitis B is one of the most common types of viral hepatitis in the world. For the last thirty years, only serological markers and liver function test have been utilized to monitor the disease progression and treatment response until the emergence of molecular detection methods. Hepatitis B V DNA quantitation is used extensively world wide for the diagnosis andmonitoring of treatment of Hepatitis B virus (HBV) infection. The aim of this study was to quantitate HBV–DNA by Real time PCR method and to compare the results with HBe Ag detection in Hepatitis B patients.
Material and Methods: Seventy one serumsamples of patients with hepatitis (all HBs Ag positive) were the subjects of this study. Serum HBV DNA of all these samples was detected by COBAS Taq Man real time PCR and HBe Ag by ELISA.
Results: Amongst Hepatitis B group patients, serum HBV DNA was detected in 61 out of 71 patients (85.9%). HBe Ag was positive in 21% of patients (15/71). Majority of the HBe Ag positive patients had a significantly higher serum HBV DNA levels than HBe Ag negative patients.
Conclusion: HBe Ag status did not necessarily reflect HBV-DNA level in the serum, as 46/71 (64.7%) in the Hepatitis B group were positive for HBV DNA but negative for HBe Ag.
Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45
Parkin DM, Pisani P, Munoz N, Ferlay J. The global health burden of incidence of infection associated cancers. Cancer surv 1999;33:25-33
Gitlin N. Hepatitis B: Diagnosis, prevention and treatment. Clin Chem1997;43:1500-6
Yamamoto K, Hori Kita M, Tsuda F. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in HB seropositive for antibody to hepatitis surface antigen.
J Virol 68:2671-6.
Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the “healthy” HBs Ag carrier state. Hepatology 1987; 7: 758-63.
Kaneko S, Miller RH, Di Bisceglie AM, Feinstone SM, Hoofnagle JH, Purcell RH. Detection of hepatitis B virus DNAin serumby polymerase chain reaction: application for clinical diagnosis. Gastroenterology1990; 99: 799-804.
Honkoop P, Niesters HG, Man RA de, Ostehaus AD, Schalm SW. Lamivudine resistance in immunocompromised chronic Hepatitis B. Incidence and patterns. J Hepatol 1997;26: 1393-5
Niesters HG, Honkoop P, Haagsma EB, Man RA de, Schalm SW, Osterhauts AD. Identification ofmore than onemutation in the Hepatitis B virus polymerase gene arising during prolonged Lamivudine treatment. J Infect Dis 1998;177:1382-5
Heo J, Baik TH, Kim HH, Kim GH, Kang DH, Song GA, et al. Serumhepatitis B virus (HBV) DNA levels at different stages of clinical course in patients with chronic HBV infection in an endemic area. J Korean Med Sci 2003; 18: 686-90
Changotra H, Dwivedi A, Nayyar AK, Sehajpal PK. Diagnosing different stages of Hepatitis B infection using a competitive polymerase chain reaction assay. IJMM 2008;26:138-42
Zaaijer HL, ter Borg F, Cuypsers HT, Hermos MG, Lelie PN. Comparison ofmethods for detection of hepatitis B virus DNA. J Clin Microbiol 1994; 32:2088-91.
Chopra GS, Gupta PK, Anand AC, Varma PP, Nair V, Ramji R. Real Time-PCR HBV-DNA Analysis: Significance and First Experience in Armed Forces. MJAFI 2005; 61:234-7